Johnson & Johnson

07/22/2024 | Press release | Distributed by Public on 07/22/2024 06:03

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression